A New Era in Cardiac Device Diagnostics: The Shift Toward Non-Invasive Monitoring

Cardiac implantable electronic devices (CIEDs) such as pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems have transformed the management of cardiovascular disease. However, traditional follow-up of these devices has historically relied on periodic in-clinic interrogations involving physical connections to bulky programmers and, in some cases, invasive lead measurements. While effective, these methods impose logistical burdens on patients and healthcare systems and carry small but real risks of infection, device dislodgement, and discomfort. In response, the last decade has witnessed a rapid expansion of non-invasive techniques for cardiac device diagnostics and monitoring. These innovations leverage advanced sensors, wireless telemetry, and novel imaging modalities to capture physiological data without direct patient contact, offering a path toward continuous, real-time, and patient-centric care.

This article provides an up-to-date review of the most promising non-invasive approaches, their current clinical applications, and the evidence supporting their use. We also discuss the challenges that remain and the future directions that will shape how clinicians monitor cardiac devices and manage the patients who rely on them.

Core Non-Invasive Monitoring Modalities

Wearable and Patch-Based Electrocardiography

The electrocardiogram remains the cornerstone of cardiac arrhythmia detection. Recent advances have miniaturized ECG technology into lightweight, adhesive patches that can be worn for days to weeks without disrupting daily life. Devices such as the Zio Patch (iRhythm Technologies) and the Carnation Ambulatory Monitor (Bardy Diagnostics) provide continuous single-lead or multi-lead recordings with high signal fidelity. For patients with CIEDs, these wearables can capture intermittent device malfunctions—such as failure to capture, undetected arrhythmias, or inappropriate shocks—that might be missed during a brief in-clinic rhythm strip. Moreover, many modern wearables incorporate Bluetooth or cellular connectivity to transmit data directly to a secure cloud platform, allowing clinicians to review tracings and receive alerts in near real time. A 2020 study published in Heart Rhythm found that patch-based monitoring had a diagnostic yield for arrhythmias comparable to that of conventional Holter monitors but with significantly improved patient adherence (A. I. E. et al., Heart Rhythm, 2020). The convenience and comfort of these devices make them an attractive option for longitudinal monitoring after CIED implantation.

Photoplethysmography: Beyond Consumer Wearables

Photoplethysmography (PPG) uses an optical sensor to detect changes in blood volume in subcutaneous tissue. While commonly associated with smartwatches and fitness trackers, PPG is increasingly being validated for clinical-grade heart rate and rhythm assessment. For patients with CIEDs, PPG can serve as a complementary screening tool for atrial fibrillation (AF) and may help detect rapid ventricular rates that could indicate device-triggered pacing problems. The Apple Heart Study (NCT03335811) demonstrated that a smartwatch-based PPG algorithm could identify irregular pulse episodes with a positive predictive value of 0.84 for AF when confirmed by simultaneous ECG patch monitoring. Importantly, PPG does not require skin preparation or adhesive electrodes, making it ideal for long-term passive monitoring. However, limitations include susceptibility to motion artifact, poor signal in patients with low perfusion, and the inability to directly assess device-specific parameters such as pacing spikes or lead impedance. Ongoing research is exploring hybrid solutions that combine PPG with a brief single‑lead ECG to overcome these gaps.

Non-Invasive Imaging for Device Assessment

Imaging plays a critical role in evaluating device placement, lead integrity, and the interaction between the device and cardiac structures. Traditionally, chest radiography and fluoroscopy have been used, but newer non-invasive modalities provide far more detail without ionising radiation exposure.

  • Echocardiography: Transthoracic echocardiography (TTE) and, when needed, transoesophageal echocardiography (TOE) can assess lead position, rule out thrombus on leads, and evaluate ventricular function. Strain imaging techniques have shown promise in detecting early changes in myocardial mechanics that precede clinical heart failure—a key event in CIED patients.
  • Cardiac MRI (CMR): With the advent of MRI-conditional CIEDs, cardiac MRI has become feasible for many patients. CMR offers unparalleled soft‑tissue contrast, enabling assessment of myocardial fibrosis, scar burden (relevant for ICD therapy), and precise lead location. A 2022 consensus statement from the Society for Cardiovascular Magnetic Resonance outlined safety protocols that have dramatically expanded the use of CMR in device patients.
  • Cardiac CT: ECG-gated cardiac CT provides high‑resolution anatomical imaging of leads, especially in the coronary sinus and left ventricle. It is increasingly used to guide lead extraction planning and to evaluate for lead perforation or vegetation when infection is suspected.

These imaging techniques are non-invasive, but they require patient cooperation and, in the case of CMR, careful adherence to manufacturer‑specific safety guidelines. Their integration into routine device follow‑up is growing, particularly in tertiary centres.

Specialised Non-Invasive Techniques for Specific Device Parameters

Impedance Monitoring for Heart Failure Prediction

One of the most clinically impactful non‑invasive techniques is transthoracic bioimpedance monitoring. When applied through the leads of a CIED (intrathoracic impedance), it can detect early increases in pulmonary fluid that precede hospitalisation for heart failure. The OptiVol system (Medtronic) and others have been validated in large trials such as PARTNERS-HF, which showed that device‑based impedance monitoring combined with other parameters had a sensitivity of 70% for predicting heart failure events. More recently, non‑invasive wearable bioimpedance sensors—placed on the thorax or limbs—have been developed to offer a similar capability without requiring an implanted device. These sensors deliver a small alternating current and measure the voltage drop across the chest, deriving indices of fluid content. Although still experimental, early studies suggest that they might serve as a bridge for patients who are not yet candidates for a CIED or as a backup monitoring system for those with implanted devices.

Acoustic and Vibrational Sensing

Another emerging frontier is the use of acoustic sensors to capture heart sounds, valve closures, and mechanical vibrations. A tiny microphone embedded in a wearable patch or even integrated into a smartphone can record the first and second heart sounds (S1, S2) and detect abnormal third or fourth sounds (S3, S4) that correlate with left ventricular dysfunction. For CIED patients, acoustic monitoring can potentially assess the efficacy of cardiac resynchronisation therapy by measuring the timing of the mechanical events (aortic and pulmonary valve closure) relative to the pacing stimulus. In a proof‑of‑concept study, the combination of acoustic data with ECG from a single wearable sensor achieved over 90% accuracy in classifying CRT response. Challenges include ambient noise filtering and the need for individualised acoustic templates, but ongoing machine‑learning projects are rapidly addressing these hurdles.

Advantages of Non-Invasive Strategies Over Traditional Approaches

  • Patient comfort and adherence: No needles, no wires, and minimal lifestyle restrictions. Patch ECG wearers report significantly higher compliance rates than Holter users. Wearable PPG devices can be worn indefinitely without discomfort, encouraging continuous data collection.
  • Reduced infection risk: Every invasive procedure carries a risk of introducing pathogens. Non‑invasive monitoring eliminates skin breaks and contact with implanted hardware, drastically reducing the chance of device‑related infections—a complication that carries high morbidity and cost.
  • Real‑time remote monitoring: Many non‑invasive systems automatically transmit data to cloud‑based platforms. This enables clinicians to track trends (e.g., nocturnal heart rate, activity level, arrhythmia burden) and receive alerts for clinically significant events without requiring the patient to travel to a clinic. During the COVID‑19 pandemic, this capability proved critical for maintaining chronic device surveillance.
  • Expanded access: Patients in rural or underserved areas can benefit from home‑based monitoring that previously required specialist visits. Additionally, non‑invasive tools can be deployed in general cardiology settings without the need for specialised device programmers.
  • Cost efficiency: Although upfront costs for wearables and cloud infrastructure exist, they are often offset by reductions in emergency department visits, hospitalisations for heart failure, and routine in‑clinic device checks. A 2021 health economic analysis from the UK estimated that remote non‑invasive monitoring for CIED patients could save approximately £1,200 per patient per year.

Current Limitations and Barriers to Adoption

Despite their promise, non‑invasive techniques are not yet ready to fully replace conventional device interrogation. Several limitations must be acknowledged.

  • Data accuracy and validation: While ECG patches are well validated for arrhythmia detection, newer modalities like PPG and bioimpedance have accuracy that varies by patient population, skin tone, and movement state. False‑positive alerts can lead to unnecessary clinical visits and patient anxiety. Rigorous clinical trials comparing non‑invasive outputs to gold‑standard device telemetry are still needed.
  • Lack of direct device parameter access: Non‑invasive sensors cannot read stored device diagnostics such as lead impedance trends, battery voltage, or pacing threshold data. A patient with a CIED will still require periodic in‑clinic or remote device‑specific checks to verify the health of the implant itself. The non‑invasive tools complement but do not replace formal device interrogation.
  • Data overload and integration: Continuous monitoring generates vast amounts of data that can overwhelm clinicians. Without robust machine‑learning algorithms and integrated electronic health record (EHR) systems, the risk of missing critical information increases. Many current platforms lack standardised output formats.
  • Reimbursement and regulatory hurdles: In many healthcare systems, codes for non‑invasive remote monitoring services are either nonexistent or limited to specific diseases (e.g., AF). The U.S. Centers for Medicare & Medicaid Services recently expanded coverage for remote physiological monitoring, but specifics vary. Regulatory clearance for novel wearable sensors also lags behind their technical development.
  • Patient acceptance and digital literacy: Older adults—who constitute the majority of CIED recipients—may be unfamiliar with smartphones or wearable technology. User‑friendliness and clear onboarding instructions are essential to avoid low adoption rates.

Future Directions: Integration, Intelligence, and Personalisation

Artificial Intelligence and Predictive Analytics

Machine‑learning models are being trained on large datasets that combine non‑invasive sensor streams (ECG, PPG, impedance, acoustic) with outcomes such as hospitalisation, mortality, and appropriate device therapy. These models can identify subtle patterns—for instance, a slight prolongation of the QRS duration detected from a patch ECG combined with a drop in thoracic impedance might predict an impending heart failure exacerbation days before symptoms appear. Early prototypes have demonstrated area‑under‑the‑curve (AUC) values exceeding 0.85 for predicting 30‑day readmission in heart failure. The challenge is to move these algorithms from research labs into FDA‑cleared software that integrates directly into clinical workflows.

Multi‑Sensor Platforms

The future likely belongs to multi‑modal wearable patches that simultaneously capture ECG, PPG, impedance, temperature, and motion signals. Such a platform could provide a nearly comprehensive picture of a CIED patient’s cardiovascular status. Companies like BioIntelliSense and VitalConnect already market single‑use patches with multiple sensors, and next‑generation devices are being designed for 30‑day continuous wear with rechargeable batteries. The data fusion from multiple sensors will improve diagnostic accuracy and reduce false alarms compared to any single modality.

Smartphone‑Based Monitoring

Smartphones already contain PPG sensors (in the camera/flash combination) and microphones capable of recording heart sounds. Several CE‑marked and FDA‑cleared apps can now perform a validated single‑lead ECG when the user places their fingers on the electrodes. For CIED patients, this means that a simple smartphone attachment can provide rhythm monitoring on demand. Large‑scale studies such as the Huawei Heart Study (2023) have shown that smartphone PPG can screen for AF with sensitivity and specificity comparable to a 12‑lead ECG in certain populations. Integrating these capabilities directly into the health‑focused ecosystem of a patient’s phone removes the need for additional hardware, potentially democratising access to non‑invasive monitoring.

Home‑Based Imaging

While far‑fetched today, portable ultrasound devices that connect to a smartphone are already approved for limited clinical use (e.g., the Butterfly iQ). As image quality improves and artificial intelligence automates image interpretation, it is conceivable that a patient or visiting nurse could obtain a focused cardiac ultrasound at home to assess device lead position or pericardial effusion. Such a development would further extend the reach of non‑invasive monitoring.

Conclusion: A Complementary, Not Replacement, Evolution

Emerging non‑invasive techniques are reshaping the landscape of cardiac device diagnostics and monitoring. They offer tangible benefits in patient comfort, safety, and data richness. However, they are not yet a substitute for definitive device interrogation. Instead, they serve as a force multiplier—extending the eyes and ears of the cardiologist beyond the clinic wall, enabling earlier detection of clinical deterioration, and empowering patients to take a more active role in their care.

The evidence base supporting these tools is growing rapidly. For further reading on clinical trial data, the American Heart Association Scientific Sessions and PubMed host numerous studies on wearable ECG and PPG validation. The FDA’s Device Database provides regulatory status of specific cleared products. Additionally, the Heart Rhythm Society publishes consensus documents on remote monitoring best practices. As the technology matures and integration with electronic health records and artificial intelligence deepens, non‑invasive monitoring will undoubtedly become a standard component of comprehensive follow‑up for patients with cardiac implantable electronic devices, ultimately improving outcomes for millions worldwide.